|
|
|
|
|
|
|
|
|
30.07.26 - 15:36
|
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel (GlobeNewswire EN)
|
|
|
SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for the treatment of cardiomyopathy in patients with Duchenne muscular dystrophy (DMD), a rare and life-threatening disease for which no approved cardiomyopathy treatment currently exists (3 for, 9 against, 0 abstain). The Committee's vote is non-binding....
|
|
|
30.07.26 - 13:45
|
XFRA: 4LN2: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
CAPRICOR THERAP. DL-,001 4LN2 US14070B3096
AB/FROM ONWARDS 30.07.2026 13:33 CET...
|
|
|
|
|
|
|
|
|
|
|
29.07.26 - 13:48
|
XFRA: 4LN2: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
CAPRICOR THERAP. DL-,001 4LN2 US14070B3096 BAW/UFN...
|
|
|
|
|
28.07.26 - 11:30
|
Capricor-Aktie -64%: Alles blickt auf morgen – was ist jetzt zu tun? (Sharedeals)
|
|
|
Die Aktie von Capricor Therapeutics ist nach der Veröffentlichung kritischer Unterlagen der US-Arzneimittelbehörde FDA massiv unter Druck geraten. Zweifel an der Aussagekraft der klinischen Studiendaten für die Zelltherapie Deramiocel haben die Hoffnungen auf eine zeitnahe Zulassung deutlich gedämpft und Investoren verunsichert. Die Aktie stürzte zeitweise um fast 70 Prozent ab. Zweifel an Studiendaten erschüttern Vertrauen […]
The post Capricor-Aktie -64%: Alles blickt auf morgen – was ist jetzt zu tun? first appeared on sharedeals.de....
|
|
|
27.07.26 - 17:03
|
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel (GlobeNewswire EN)
|
|
|
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today provided an update ahead of the Company's upcoming FDA Advisory Committee meeting, at which an independent advisory committee will discuss Capricor's Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD), as part of the FDA's ongoing review of the application....
|
|
|
|
|
|
|
|
|
|
|
26.06.26 - 15:09
|
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference (GlobeNewswire EN)
|
|
|
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company's lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company's HOPE-3 Phase 3 trial....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
